Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.
Cruz-Migoni, A., Canning, P., Quevedo, C.E., Bataille, C.J.R., Bery, N., Miller, A., Russell, A.J., Phillips, S.E.V., Carr, S.B., Rabbitts, T.H.(2019) Proc Natl Acad Sci U S A 116: 2545-2550
- PubMed: 30683716 
- DOI: 10.1073/pnas.1811360116
- Primary Citation of Related Structures:  
6GOD, 6GOE, 6GOF, 6GOG, 6GOM, 6GQT, 6GQW, 6GQX, 6GQY - PubMed Abstract: 
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS 169 Q61H -yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance ...